RxDoctor Payments Data

Amr Barakat, MD

Cardiovascular Disease · Jacksonville, FLNPI 1508270448

Payments from drug & device makers

$43,332in general payments, 2019–2025

Across 129 payments — averaging $335.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$17K
  • Medtronic$16K
  • Boston Scientific$9K
  • Biosense Webster, Inc.$336
  • Cardiva Medical, Inc.$259
  • Cardiofocus, Inc.$239
  • plus $740 from 10 others
$5,000in research payments, 2019–2025

Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vektor Medical Inc.$5K

What the payments were for

  • Consulting fees$5,77513%
  • Grants$26,58361%
  • Travel & lodging$6,61115%
  • Food & beverage$4,0429%
  • Education$3211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,332 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$288,262
Medicare patients
543
Services billed
2,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$219,211
EntrestoSacubitril/Valsartan31$45,841
XareltoRivaroxaban41$42,506
MultaqDronedarone Hcl15$11,150
PradaxaDabigatran Etexilate Mesylate12$2,402
Flecainide Acetate34$1,285
Metoprolol Succinate98$1,224
Amiodarone Hcl90$1,042
Pantoprazole Sodium54$288
SotalolSotalol Hcl15$245
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$211
Atorvastatin Calcium30$165
Carvedilol19$96
ClopidogrelClopidogrel Bisulfate15$95
Metoprolol Tartrate23$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$17$42,50641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →